The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum

Launched by UMC UTRECHT · Apr 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called etidronate on a condition known as Pseudoxanthoma Elasticum (PXE). PXE is a genetic disorder that can lead to unwanted calcification in the body, particularly in the arteries. In this trial, researchers want to find out if taking etidronate for 24 months can reduce calcification in the legs and neck arteries compared to a placebo (a pill with no active medication). Participants will undergo low-dose CT scans to measure any changes in arterial calcification after treatment.

To be eligible for this trial, participants must be between 18 and 50 years old and have a confirmed diagnosis of PXE based on specific criteria related to skin, eye, or genetic tests. It's important to note that women who can become pregnant must use effective contraception during the study. Those who join the study will take either etidronate or a placebo for two years and will have regular check-ups to monitor their health. This trial is currently recruiting participants, and it aims to improve understanding and treatment options for PXE.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• In order to be eligible to participate in this study, a subject must meet all of the following criteria:
• • 1. Be between 18 years and 50 years.
• * 2. Have a definitive diagnosis of PXE according to the Plomp criteria, which confirm a diagnosis of PXE when at least two (or more) criteria not belonging to the same category (skin, eye, genetic) are met:
• • 1. Skin
• • 1. Yellowish papules and/or plaques on the lateral side of the neck and/or flexural areas of the body or
• • 2. Increase of morphologically altered elastin with fragmentation, clumping and calcification of elastic fibers in a skin biopsy taken.
• • 2. Eye
• • 1. Peau d'orange of the retina or
• • 2. One or more angioid streaks (AS), each at least as long as one disk diameter. When in doubt, fluorescein or indocyanine green angiography of the fundus is needed for confirmation.
• • 3. Genetics
• • 1. A pathogenic mutation of both alleles of the ABCC6 gene or
• • 2. A first-degree relative (parent, sibling or child) who meets independently the diagnostic criteria for definitive PXE
• • 3. Fertile women must take adequate anticonception.
• Exclusion Criteria:
• A potential subject who meets any of the following criteria will be excluded from participation in this study:
• • 1. Patients that are unable or unwilling to sign for informed consent.
• • 2. Pregnant, lactating, or fertile women who might wish to become pregnant within three years.\*\*
• • 3. Patients with an estimated glomerular filtration rate below 30 ml/min/1.73m2 according to the CKD-EPI equation.31
• • 4. Patients with a known abnormality of the oesophagus that would interfere with passage of the drug (e.g. oesophagus stenosis).
• • 5. Patients with chronic diarrhoea (\> 1 month).
• • 6. Patients with known osteomalacia;
• • 7. Patients with hypocalcaemia (calcium \<2.20 mmol/L corrected for albumin)\*.
• • 8. Patients with a vitamin D deficiency (\<35 nmol/L)\*.
• • 9. Patients that used a bisphosphonate in the last 5 years.
• • 10. Patients with known sensitivity to etidronate.
• • 11. Any other medical or social condition that, at the discretion of the Principal Investigator, might put the subject at risk of harm during the study or might adversely affect the interpretation of the study data.
• • After correction a patient is again suitable for participation, as long as inclusion criteria are met (more information in paragraph 7.3.3).
• • Subjects that become pregnant during the trial will be excluded from further participation.